All In Biotech

Drug Trial Radar · NCT06120140

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 305 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

305

Actual

Start

Feb 16, 2024

Primary completion

May 31, 2027

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade \>=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Amivantamab IVDrug

    Amivantamab will be administered.

  • Amivantamab SCDrug

    Amivantamab will be administered as SC injection.

  • LazertinibDrug

    Lazertinib tablet will be administered orally.

  • DoxycyclineDrug

    Doxycycline tablet will be administered orally.

  • MinocyclineDrug

    Minocycline capsule will be administered orally.

  • ClindamycinDrug

    Clindamycin lotion will be used as topical application on the scalp.

  • ChlorhexidineDrug

    Chlorhexidine solution will be used as topical application on hands and feet.

  • Noncomedogenic skin moisturizerOther

    Noncomedogenic skin moisturizer will be used as topical application.

  • RuxolitinibOther

    Ruxolitinib will be used to the affected skin area.

  • TacrolimusOther

    Tacrolimus will be used as topical application to the affected skin area.

  • Zinc gluconateDrug

    Zinc gluconate tablet will be administered.

  • PropranololDrug

    Propranolol tablet will be administered.

  • TimololDrug

    Timolol will be used to the affected skin area.

  • ClobetasolDrug

    Clobetasol shampoo will be used on the scalp.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer TreatmentTime frame: Up to 12 weeks after initiation of anticancer treatment

Locations

93 sites in 11 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Center

    Chandler, Arizona

  • City of Hope

    Duarte, California

  • Providence Fullerton

    Fullerton, California

  • Los Angeles Cancer Network

    Glendale, California

  • City of Hope Seacliff

    Huntington Beach, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California

  • City of Hope Long Beach Elm

    Long Beach, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Keck Hospital of USC

    Los Angeles, California

  • USC Norris Oncology Hematology Newport Beach

    Newport Beach, California

  • Kaiser Permanente Oakland Medical Center

    Oakland, California

  • Kaiser Permanente Roseville Medical Center

    Roseville, California

  • Kaiser Permanente San Francisco Medical Center

    San Francisco, California

  • Kaiser Permanente Santa Clara Medical Center

    Santa Clara, California

  • City of Hope South Pasadena

    South Pasadena, California

  • Kaiser Permanente Northern California

    Vallejo, California

  • Kaiser Permanente Walnut Creek Medical Center

    Walnut Creek, California

  • University Cancer & Blood Center

    Athens, Georgia

  • Hope and Healing Care

    Hinsdale, Illinois

  • Oncology Hematology Associates

    Springfield, Missouri

  • Renown Health Medical Oncology

    Reno, Nevada

  • Hunterdon Hematology Oncology

    Flemington, New Jersey

  • Clinical Research Alliance Inc

    Westbury, New York

  • Regional Medical Oncology Center

    Wilson, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Valley Medical Center

    Renton, Washington

  • Gundersen Health System

    West Salem, Wisconsin

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • IADT Instituto Argentino de Diagnostico y Tratamiento

    CABA, Argentina

  • Centro Medico Austral

    Capital Federal, Argentina

  • Hospital Italiano de La Plata

    La Plata, Argentina

  • Hospital Privado de la Comunidad

    Mar del Plata, Argentina

  • CTO Centro De Tratamento Oncologico LTDA

    Belém, Brazil

  • Santa Casa de Misericordia de Belo Horizonte

    Belo Horizonte, Brazil

  • Liga Paranaense de Combate ao Cancer

    Curitiba, Brazil

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil

  • Hospital Nossa Senhora da Conceicao S A

    Porto Alegre, Brazil

  • Nucleo de Oncologia da Bahia Oncoclinicas

    Salvador, Brazil

  • Hospital Ana Nery Santa Cruz do Sul

    Santa Cruz do Sul, Brazil

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.